Repurposing amino-bisphosphonates by liposome formulation for a new role in cancer treatment
- 1 January 2021
- journal article
- research article
- Published by Elsevier in Seminars in Cancer Biology
- Vol. 68, 175-185
Abstract
No abstract availableKeywords
Funding Information
- National Cancer Institute (R15CA192097, R15CA182769)
- CPRIT (RP150656)
This publication has 101 references indexed in Scilit:
- Zoledronic Acid Sensitizes Renal Cell Carcinoma Cells to Radiation by Downregulating STAT1PLOS ONE, 2013
- Liposome encapsulation of zoledronic acid results in major changes in tissue distribution and increase in toxicityJournal of Controlled Release, 2013
- Making Sense of the Cytokine Storm: A Conceptual Framework for Understanding, Diagnosing, and Treating Hemophagocytic SyndromesPediatric Clinics of North America, 2012
- Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironmentClinical and Experimental Immunology, 2012
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast CancerNew England Journal of Medicine, 2009
- Peripheral blood monocytes are responsible for γδ T cell activation induced by zoledronic acid through accumulation of IPP/DMAPPBritish Journal of Haematology, 2008
- Preparation of Alendronate Liposomes for Enhanced Stability and Bioactivity: In Vitro and In Vivo CharacterizationThe AAPS Journal, 2008
- Amino-Biphosphonate–Mediated MMP-9 Inhibition Breaks the Tumor-Bone Marrow Axis Responsible for Myeloid-Derived Suppressor Cell Expansion and Macrophage Infiltration in Tumor StromaCancer Research, 2007
- Pharmacokinetics of AlendronateClinical Pharmacokinetics, 1999